176 related articles for article (PubMed ID: 35345739)
1. Molecular Testing of Atypical Thyroid Nodules with Corresponding Surgical Correlation: Five-Year Retrospective Review in Veterans Population.
Carr DM; Mastorides S; Stobaugh C; Carlton G; DeLand L; Borkowski A
Cureus; 2022 Feb; 14(2):e22536. PubMed ID: 35345739
[TBL] [Abstract][Full Text] [Related]
2. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
3. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
4. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
Hyeon J; Ahn S; Shin JH; Oh YL
Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
[TBL] [Abstract][Full Text] [Related]
5. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
6. Risk Stratification Study of Indeterminate Thyroid Nodules with a next-generation Sequencing Assay with Residual ThinPrep® Material.
Zhao H; Jing W; Li W; Zhang Z; Cao J; Zhao L; Sun Y; Wang C; Wang Y; Guo H
J Cancer; 2020; 11(24):7276-7282. PubMed ID: 33193891
[No Abstract] [Full Text] [Related]
7. Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF
Chirayath SR; Pavithran PV; Abraham N; Nair V; Bhavani N; Kumar H; Menon UV; Menon AS
Indian J Endocrinol Metab; 2019; 23(3):278-281. PubMed ID: 31641627
[TBL] [Abstract][Full Text] [Related]
8. Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine-needle aspiration.
Partyka KL; Trevino K; Randolph ML; Cramer H; Wu HH
Diagn Cytopathol; 2019 Sep; 47(9):853-862. PubMed ID: 31245935
[TBL] [Abstract][Full Text] [Related]
9. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY
Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
[TBL] [Abstract][Full Text] [Related]
10. A meta-analytic review of the Bethesda System for Reporting Thyroid Cytopathology: Has the rate of malignancy in indeterminate lesions been underestimated?
Straccia P; Rossi ED; Bizzarro T; Brunelli C; Cianfrini F; Damiani D; Fadda G
Cancer Cytopathol; 2015 Dec; 123(12):713-22. PubMed ID: 26355876
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
12. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.
Nikiforov YE; Ohori NP; Hodak SP; Carty SE; LeBeau SO; Ferris RL; Yip L; Seethala RR; Tublin ME; Stang MT; Coyne C; Johnson JT; Stewart AF; Nikiforova MN
J Clin Endocrinol Metab; 2011 Nov; 96(11):3390-7. PubMed ID: 21880806
[TBL] [Abstract][Full Text] [Related]
13. Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: A comparison of two proprietary testing platforms.
Partyka KL; Randolph ML; Lawrence KA; Cramer H; Wu HH
Diagn Cytopathol; 2018 Apr; 46(4):320-325. PubMed ID: 29446257
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
[TBL] [Abstract][Full Text] [Related]
15. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
Labourier E; Shifrin A; Busseniers AE; Lupo MA; Manganelli ML; Andruss B; Wylie D; Beaudenon-Huibregtse S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2743-50. PubMed ID: 25965083
[TBL] [Abstract][Full Text] [Related]
16. Indeterminate Thyroid Fine-Needle Aspirations in Pediatrics: Exploring Clinicopathologic Features and Utility of Molecular Profiling.
Baran JA; Halada S; Bauer AJ; Ricarte-Filho JC; Isaza A; Surrey LF; McGrath C; Bhatti T; Jalaly J; Mostoufi-Moab S; Franco AT; Adzick NS; Kazahaya K; Cahill AM; Baloch Z
Horm Res Paediatr; 2022; 95(5):430-441. PubMed ID: 35871517
[TBL] [Abstract][Full Text] [Related]
17. A histological assessment of the Bethesda system for reporting thyroid cytopathology (2010) abnormal categories: a series of 219 consecutive cases.
Tepeoğlu M; Bilezikçi B; Bayraktar SG
Cytopathology; 2014 Feb; 25(1):39-44. PubMed ID: 23438201
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of molecular testing in cytologically indeterminate thyroid nodules with histologic correlation: Experience at a heterogenous multihospital system.
Sura GH; Thrall MJ; Rogers J; Hodjat P; Christensen P; Cubb TD; Khadra HS; Thomas JS; Jacobi EM
Diagn Cytopathol; 2024 Feb; 52(2):82-92. PubMed ID: 37950548
[TBL] [Abstract][Full Text] [Related]
19. Thyroid cytology-nuclear versus architectural atypia within the "Atypia of undetermined significance/follicular lesion of undetermined significance" Bethesda category have significantly different rates of malignancy.
Gan TR; Nga ME; Lum JH; Wong WM; Tan WB; Parameswaran R; Ngiam KY
Cancer Cytopathol; 2017 Apr; 125(4):245-256. PubMed ID: 28192631
[TBL] [Abstract][Full Text] [Related]
20. Rethinking Malignancy Risk in Indeterminate Thyroid Nodules with Positive Molecular Studies: Southern California Permanente Experience.
Cohen DS; Tongson-Ignacio JE; Lolachi CM; Ghaderi VS; Jahan-Parwar B; Thompson LDR
Otolaryngol Head Neck Surg; 2019 Sep; 161(3):419-423. PubMed ID: 31013183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
